Ph.D. (1991) Instituto Karolinska, Suecia

Líneas de Investigación

Tumor immunology Lab major interest has been focused in several aspects of tumor immunology, from basic research to clinical trials. We described the effect of a cytokine IL-10 on tumor antigen presentation inhibition and how the expression of IL-10 could be used by tumors to evade the immune system. Using a short peptide, homologous to IL-10 functional domain he has shown that the peptide can affect antigen presentation in tumors and maturation of dendritic cells, a found which can be very relevant, not only for tumor immunology, without also for autoimmunity (J.Immunol. 2004, Immunobiology 2011). We have also identified and characterized new melanoma antigens derived from the Melanocortin 1 receptor, which he demonstrated to be over-expressed in primary and metastatic melanoma (British J Immunol.2005). Antibodies directed to this protein have been demonstrated to be excellent for the diagnosis of ocular melanoma (IOVPS, 2007). During the last six years, Dr. Salazar has organized and leads a multidisciplinary group of scientist that includes physicians, with specialties in oncology and immunology, together with biologists, and biochemists. We built the first GMP facilities for manipulation of human cells and performed the first Phase I and Phase I/II clinical trials in Chile of immunotherapy based on dendritic cells for the treatment of melanoma and also for prostate cancer. The results of these clinical studies have been published in high impact international journals such asClin. Exp. Immunol. (2005); J. Clin. Oncol. (2008) and Clin. Cancer Research (2011). He and his group invented an original method to produce dendritic cells ex vivo. This method is protected by an applied international patent (PCT/EP2008/062909).

Publicaciones Recientes

  1. Tittarelli A, Guerrero I, Tempio F, Gleisner MA, Avalos I, Sabanegh S, Ortiz C, Michea L, López MN, Mendoza-Naranjo A, Salazar-Onfray F. “Overexpression of connexin 43 reduces melanoma proliferative and metastatic capacity”. Br J Cancer. (2015) Jul 14; 113(2): 259-67 ISSN: 0007-0920. IF: 4.836
  2. Pérez CA, Rabanales R, Rojas-Alcayaga G,Larrondo M, Escobar AF, López MN, Salazar-Onfray F, Alfaro JI, González FE. “Dendritic cell chimerism in oral mucosa of transplanted patients affected by graft- versus host disease”. J. Oral Pathol Med. (2015) Jun 23 doi:10.1111/ jop 12338. ISSN: 1600-0714. IF: 1.926
  3. González FE, Ortiz C, Reyes M, Dutzan N, Patel V, Pereda C, Gleisner MA, López MN, Gutkind JS, Salazar-Onfray F. 2014. “Melanoma cell lysate induces CCR7 expression and in vivo migration to draining lymph nodes of therapeutic human dendritic cells”. (2014) Jul; 142(3):396-405. ISSN: 1365-2567. IF: 3.795
  4. Tittarelli A, Mendoza-Naranjo A, Farías M, Guerrero I, Ihara F, Wennerberg E, Riquelme S, Gleisner A, Kalergis A, Lundqvist A, López MN, Chambers BJ, Salazar-Onfray F. “Gap junction intercellular communications regulate NK cell activation and modulate NK cytotoxic capacity”. J Immunol.(2014) Feb 1;192 (3):1313-9. ISSN: 0022-1767. IF= 4.922 (10 Citations)
  5. González FE, Gleisner A, Falcón –Beas F, Osorio F, López MN, Salazar-Onfray F. “Tumor cell lysates as immunogenic sources for cáncer vaccine design”. Hum Vaccin Immunother.2014; 10(11):3261-9. ISSN: 2164-5515. IF: 2.366
  6. González FE, Ramírez M, Allerbring EB, Fasching N, Lundqvist A, Poschke I, Achour A, Salazar-Onfray F. 2014. “Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients”. Immunobiology. (2014) Mar;219(3):189-97. ISSN: 0171-2985. IF: 3.044
  7. Mackern-Oberti JP, Llanos C, Vega F, Salazar-Onfray F, Riedel CA, Bueno SM, Kalergis AM. “Role of dendritic cells in the initiation, progress and modulation of systemic autoimmune disease”. Autoimmun Rev. 2015 eb; 14(2):127-39doi:10.1016/j.autrev.2001410.010 Epub 2014 Oct 14. ISSN: 1568-9972. IF: 7.93
  8. Salazar-Onfray F, Pereda C, Reyes D, MN López. TAPCells, the chilean dendritic cell vaccine against melanoma and prostate cancer”. Biol Res (2013)46(4):431-440. ISSN: 0.717-6287. IF: 1.480
  9. D. Reyes, L. Salazar, E. Espinoza, C. Pereda, E. Castellón, R. Valdevenito, C. Huidobro, M Ines Becquer, A. Lladser, F. Salazar- Onfray. “Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients”. British Journal of Cancer (2013) 109, 1488–1497. doi:10.1038/bjc.2013.494. ISSN: 0007-0920. IF: 4.836
  10. Durán-Aniotz C, Segal G, Salazar L, Pereda C, Falcón C, Tempio F, Aguilera R, González R, Pérez C, Tittarelli A, Catalán D, Nervi B, Larrondo M, Salazar-Onfray F, López MN. 2013. “The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses”. Cancer Immunol Immunother. (2013) Apr;62 (4):761-72. ISSN: 0340-7004. IF:3.941 (1 citations)